ClinicalTrials.gg
BiologicalDrug

JX-594 clinical trials

Also written JX-594.

studies test it
18
open now
0
in phase 3
1
first study started
2007

How each study uses JX-594 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pexa-Vec
6
Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
4
JX-594 recombinant vaccina GM-CSF
2
Pexastimogene Devacirepvec (Pexa Vec)
2

Development codes

JX-594
11
TG6006
1

Other names

Pexastimogene Devacirepvec
1

Studies by the year they started

18 studies that test it; most in 2010 (3)

Studies that test JX-594, by start year
YearStudies
20071
20081
20091
20103
20112
20122
20141
20152
20173
20181
20211

By phase

A phase 1/2 study counts in both.

Phase 1
12
Phase 2
12
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 13 · Other 5

Jennerex Biotherapeutics (9) · SillaJen, Inc. (2) · National Cancer Institute (NCI) (1) · Centre Leon Berard (1) · Samsung Medical Center (1) · Transgene (1) · Lee's Pharmaceutical Limited (1) · Institut Bergonié (1)

Often tested with

Tested in the same studies.

Cemiplimab (1) · Socazolimab (1) · Cyclophosphamide (1) · Avelumab (1)

Studies

Open first, then newest update. How each study uses JX-594 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 18